Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 525 | 53994-73-3 |
Dose | Unit | Route |
---|---|---|
1 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 8.59 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 52 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 67.97 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
April 4, 1979 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 645.37 | 29.13 | 322 | 3269 | 310365 | 63175066 |
Cross sensitivity reaction | 459.27 | 29.13 | 83 | 3508 | 2079 | 63483352 |
Type IV hypersensitivity reaction | 441.25 | 29.13 | 84 | 3507 | 2814 | 63482617 |
International normalised ratio fluctuation | 416.08 | 29.13 | 78 | 3513 | 2400 | 63483031 |
Bloody discharge | 306.22 | 29.13 | 56 | 3535 | 1495 | 63483936 |
Lyme disease | 255.91 | 29.13 | 55 | 3536 | 3394 | 63482037 |
Rash maculo-papular | 166.75 | 29.13 | 64 | 3527 | 31832 | 63453599 |
Therapeutic product effect incomplete | 107.44 | 29.13 | 74 | 3517 | 124982 | 63360449 |
Infection | 90.45 | 29.13 | 86 | 3505 | 229087 | 63256344 |
Oedema | 70.44 | 29.13 | 52 | 3539 | 97570 | 63387861 |
Drug intolerance | 62.89 | 29.13 | 82 | 3509 | 308579 | 63176852 |
Iron deficiency | 62.18 | 29.13 | 21 | 3570 | 7209 | 63478222 |
Muscle tension dysphonia | 43.97 | 29.13 | 8 | 3583 | 206 | 63485225 |
Platelet count increased | 43.96 | 29.13 | 21 | 3570 | 17690 | 63467741 |
Dysphemia | 40.65 | 29.13 | 12 | 3579 | 2663 | 63482768 |
Toxic epidermal necrolysis | 36.87 | 29.13 | 21 | 3570 | 25313 | 63460118 |
Clostridium difficile infection | 36.18 | 29.13 | 22 | 3569 | 29900 | 63455531 |
Urticaria | 33.56 | 29.13 | 44 | 3547 | 165758 | 63319673 |
Vomiting | 32.03 | 29.13 | 86 | 3505 | 559531 | 62925900 |
Vaccination complication | 30.39 | 29.13 | 8 | 3583 | 1169 | 63484262 |
Immunisation reaction | 30.01 | 29.13 | 7 | 3584 | 623 | 63484808 |
Oral pruritus | 29.31 | 29.13 | 9 | 3582 | 2282 | 63483149 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 98.32 | 28.60 | 19 | 982 | 1378 | 34954552 |
Type IV hypersensitivity reaction | 91.70 | 28.60 | 18 | 983 | 1416 | 34954514 |
Drug hypersensitivity | 47.09 | 28.60 | 29 | 972 | 80500 | 34875430 |
Complex regional pain syndrome | 35.51 | 28.60 | 7 | 994 | 560 | 34955370 |
Medical device implantation | 28.92 | 28.60 | 6 | 995 | 620 | 34955310 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 537.28 | 27.62 | 102 | 4114 | 3610 | 79736562 |
Type IV hypersensitivity reaction | 527.63 | 27.62 | 102 | 4114 | 3979 | 79736193 |
Drug hypersensitivity | 517.07 | 27.62 | 269 | 3947 | 298647 | 79441525 |
International normalised ratio fluctuation | 401.44 | 27.62 | 79 | 4137 | 3375 | 79736797 |
Bloody discharge | 297.05 | 27.62 | 56 | 4160 | 1897 | 79738275 |
Lyme disease | 261.14 | 27.62 | 55 | 4161 | 3295 | 79736877 |
Rash maculo-papular | 170.89 | 27.62 | 75 | 4141 | 56003 | 79684169 |
Therapeutic product effect incomplete | 105.84 | 27.62 | 75 | 4141 | 141570 | 79598602 |
Infection | 97.21 | 27.62 | 89 | 4127 | 241623 | 79498549 |
Oedema | 95.56 | 27.62 | 66 | 4150 | 119514 | 79620658 |
Drug intolerance | 75.90 | 27.62 | 81 | 4135 | 264038 | 79476134 |
Iron deficiency | 52.00 | 27.62 | 20 | 4196 | 10634 | 79729538 |
Vomiting | 41.18 | 27.62 | 101 | 4115 | 665727 | 79074445 |
Platelet count increased | 40.61 | 27.62 | 21 | 4195 | 22385 | 79717787 |
Urticaria | 39.88 | 27.62 | 49 | 4167 | 185152 | 79555020 |
Toxic epidermal necrolysis | 38.84 | 27.62 | 26 | 4190 | 44555 | 79695617 |
Muscle tension dysphonia | 32.90 | 27.62 | 6 | 4210 | 168 | 79740004 |
None
Source | Code | Description |
---|---|---|
ATC | J01DC04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:88188 | allergenic drug |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Streptococcal tonsillitis | indication | 41582007 | |
Lower respiratory tract infection | indication | 50417007 | |
Upper respiratory infection | indication | 54150009 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Acute Moraxella catarrhalis bronchitis | indication | 195722003 | |
Acute bacterial bronchitis | indication | 233598009 | |
Pneumonia | indication | 233604007 | DOID:552 |
Streptococcus pyogenes infection | indication | 302809008 | |
Infective otitis media | indication | 312218008 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Moraxella Catarrhalis Chronic Bronchitis | indication | ||
Haemophilus Influenzae Bronchitis | indication | ||
Haemophilus Influenzae Chronic Bronchitis | indication | ||
Streptococcus Pneumoniae Bronchitis | indication | ||
Streptococcus Pneumoniae Chronic Bronchitis | indication | ||
Pyrexia of unknown origin | off-label use | 7520000 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.02 | acidic |
pKa2 | 13.93 | acidic |
pKa3 | 7.67 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | WOMBAT-PK | |||||||
Streptokinase A | Enzyme | EC50 | 6.33 | WOMBAT-PK |
ID | Source |
---|---|
4017534 | VUID |
N0000145917 | NUI |
D00256 | KEGG_DRUG |
203635 | RXNORM |
C0007537 | UMLSCUI |
CHEBI:3478 | CHEBI |
8XI | PDB_CHEM_ID |
CHEMBL680 | ChEMBL_ID |
CHEMBL1201018 | ChEMBL_ID |
DB00833 | DRUGBANK_ID |
D002433 | MESH_DESCRIPTOR_UI |
51039 | PUBCHEM_CID |
10897 | IUPHAR_LIGAND_ID |
69K7K19H4L | UNII |
4368 | MMSL |
862 | MMSL |
871 | MMSL |
d00081 | MMSL |
387270009 | SNOMEDCT_US |
4937008 | SNOMEDCT_US |
4017534 | VANDF |
70356-03-5 | SECONDARY_CAS_RN |
002726 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1087 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 24 sections |
CEFACLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9985 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
CEFACLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9986 | CAPSULE | 500 mg | ORAL | ANDA | 20 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-070 | SUSPENSION | 125 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-071 | SUSPENSION | 250 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-072 | SUSPENSION | 375 mg | ORAL | ANDA | 23 sections |
CEFACLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-782 | SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-125 | FOR SUSPENSION | 125 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-125 | FOR SUSPENSION | 125 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-250 | FOR SUSPENSION | 250 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-250 | FOR SUSPENSION | 250 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-375 | FOR SUSPENSION | 375 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-375 | FOR SUSPENSION | 375 mg | ORAL | ANDA | 24 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1602 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3478 | CAPSULE | 250 mg | ORAL | ANDA | 13 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3511 | CAPSULE | 500 mg | ORAL | ANDA | 13 sections |
CEFACLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59115-071 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
CEFACLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59115-072 | CAPSULE | 250 mg | ORAL | ANDA | 21 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-171 | CAPSULE | 250 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-172 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-173 | SUSPENSION | 125 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-174 | SUSPENSION | 187 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-175 | SUSPENSION | 250 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61442-176 | SUSPENSION | 375 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1007 | CAPSULE | 250 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1008 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68289-003 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68289-004 | CAPSULE | 250 mg | ORAL | ANDA | 23 sections |
Cefaclor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81948-6250 | SUSPENSION | 250 mg | ORAL | ANDA | 22 sections |